Literature DB >> 29304947

Trading Bankruptcy for Health: A Discrete-Choice Experiment.

Mark G Shrime1, Milton C Weinstein2, James K Hammitt2, Jessica L Cohen3, Joshua A Salomon4.   

Abstract

BACKGROUND: Although nearly two-third of bankruptcy in the United States is medical in origin, a common assumption is that individuals facing a potentially lethal disease opt for cure at any cost. This assumption has never been tested, and knowledge of how the American population values a trade-off between cure and bankruptcy is unknown.
OBJECTIVES: To determine the relative importance among the general American population of improved health versus improved financial risk protection, and to determine the impact of demographics on these preferences.
METHODS: A discrete-choice experiment was performed with 2359 members of the US population. Respondents were asked to value treatments with varying chances of cure and bankruptcy in the presence of a lethal disease. Latent class analysis with concomitant variables was performed, weighted for national representativeness. Sensitivity analyses were undertaken to test the robustness of the results.
RESULTS: It was found that 31.3% of the American population values cure at all costs. Nevertheless, for 8.5% of the US population, financial solvency dominates concerns for health in medical decision making. Individuals who value cure at all costs are more likely to have had experience with serious disease and to be women. No demographic characteristics significantly predicted individuals who value solvency over cure.
CONCLUSIONS: Although the average American values cure more than financial solvency, a cure-at-all-costs rubric describes the preferences of a minority of the population, and 1 in 12 value financial protection over any chances of cure. This study provides empirical evidence for how the US population values a trade-off between avoiding adverse health outcomes and facing bankruptcy. These findings bring to the fore the decision making that individuals face in balancing the acute financial burden of health care access.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  discrete-choice analysis; health care costs; medical bankruptcy

Mesh:

Year:  2017        PMID: 29304947      PMCID: PMC6739632          DOI: 10.1016/j.jval.2017.07.006

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  8 in total

1.  ISOPT Clinical Hot Topic Panel Discussion on Ocular Drug Delivery.

Authors:  Uday B Kompella; Abraham Domb; Arto Urtti; Ashwath Jayagopal; Clive G Wilson; Diane Tang-Liu
Journal:  J Ocul Pharmacol Ther       Date:  2019-06-28       Impact factor: 2.671

2.  Drug Costs: What Can Infectious Diseases Physicians Do?

Authors:  Shashi N Kapadia; Roy M Gulick
Journal:  J Infect Dis       Date:  2020-02-18       Impact factor: 5.226

3.  Valuing mortality risk in the time of COVID-19.

Authors:  James K Hammitt
Journal:  J Risk Uncertain       Date:  2020-11-11

4.  Patients Place More of an Emphasis on Physical Recovery Than Return to Work or Financial Recovery.

Authors:  Nathan N O'Hara; Dionne S Kringos; Gerard P Slobogean; Yasmin Degani; Niek S Klazinga
Journal:  Clin Orthop Relat Res       Date:  2021-06-01       Impact factor: 4.755

5.  "Sell an Ox" - The Price of Cure for Hepatitis C in Two Countries.

Authors:  Ora Paltiel; Workagegnehu Hailu; Zenahebezu Abay; Avram Mark Clarfield; Martin McKee
Journal:  Int J Health Policy Manag       Date:  2020-06-01

6.  Latent class analysis of the social determinants of health-seeking behaviour for delivery among pregnant women in Malawi.

Authors:  Rachel R Yorlets; Katherine R Iverson; Hannah H Leslie; Anna Davies Gage; Sanam Roder-DeWan; Humphreys Nsona; Mark G Shrime
Journal:  BMJ Glob Health       Date:  2019-03-30

7.  Health-system-adapted data envelopment analysis for decision-making in universal health coverage.

Authors:  Mark G Shrime; Swagoto Mukhopadhyay; Blake C Alkire
Journal:  Bull World Health Organ       Date:  2018-04-23       Impact factor: 9.408

8.  Distinguishing moral hazard from access for high-cost healthcare under insurance.

Authors:  Christopher T Robertson; Andy Yuan; Wendan Zhang; Keith Joiner
Journal:  PLoS One       Date:  2020-04-17       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.